Mizuho Reiterates Buy Rating on Neumora Therapeutics with $4 Target
Mizuho maintains its Buy rating on Neumora Therapeutics, setting a $4 price target.
Key Points
- On June 18, 2026, Mizuho reiterated its Buy rating on Neumora Therapeutics with a $4 target.
- Neumora Therapeutics, trading at $1.53, has a market cap of about $283.5 million and a forward P/E of -1.95.
- Insiders bought 80,000 shares each on May 27, 2026, while analysts maintain a Buy consensus with a mean target of $6.78.
Mizuho has reiterated its Buy rating on Neumora Therapeutics, Inc. (NasdaqGS: NMRA), setting a price target of $4. This update was made by analyst Graig Suvannavejh on June 18, 2026. Shares of Neumora were trading at $1.53 at the time of the report.
Other Institutional Activity in Neumora Therapeutics
SIREN, L.L.C. increased its holdings in Neumora by adding 2,209,039 shares, bringing its total to 8,497,822 shares valued at approximately $16.57 million. In contrast, SoftBank Group Corp. reduced its position by 339,419 shares, ending with 6,090,301 shares worth about $11.88 million. Perceptive Advisors LLC took a new position, acquiring 5,104,097 shares valued at nearly $9.95 million. Vanguard Capital Management LLC also established a new stake with 3,891,893 shares valued at $7.59 million.
Neumora Therapeutics Stock Snapshot
Shares of Neumora Therapeutics, Inc. (NasdaqGS: NMRA) traded near $1.53. The company has a market cap of approximately $283.5 million. Neumora's forward P/E ratio is not meaningful as the company is not currently profitable. The stock has a 52-week range between $0.716 and $3.65, with a 50-day moving average of $1.94 and a 200-day moving average of $2.19. The company shows a current ratio of 5.10 and a quick ratio of 4.88, indicating strong liquidity, though it carries a debt-to-equity ratio of 75.51.
Insider Buying and Selling at Neumora Therapeutics, Inc.
On May 27, 2026, several insiders including Matthew Fust, Maykin Ho, Kristina Burow, Alaa Halawa, and David Piacquad each purchased 80,000 shares of Neumora Therapeutics. These transactions were not under any prearranged plans.
Analysts Set New Price Targets
On June 18, 2026, Mizuho maintained its Buy rating on Neumora with a $4 price target. Earlier, on June 16, 2026, Needham and HC Wainwright & Co. also maintained Buy ratings with targets of $5 and $7, respectively. The consensus among analysts is a Buy, with an average target price of $6.78 based on eight analyst opinions.
About Neumora Therapeutics
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. It focuses on developing treatments for brain-related diseases, including major depressive disorder and Alzheimer's-related agitation. Notably, its lead product, NMRA-140, is in phase 3 clinical trials. The company was founded in 2019 and is led by CEO Dr. Joshua Pinto.
Bottom Line
Mizuho's reaffirmation of a Buy rating with a $4 target reflects continued optimism in Neumora Therapeutics' potential. Investors track such analyst updates to gauge market sentiment and potential future performance. As a reminder, these analyst ratings are based on past data and projections which may not reflect current conditions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.